Bisantrene + Fludarabine + Clofarabine
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelogenous Leukemia, Acute
Conditions
Myelogenous Leukemia, Acute
Trial Timeline
Aug 2, 2021 → Dec 1, 2025
NCT ID
NCT04989335About Bisantrene + Fludarabine + Clofarabine
Bisantrene + Fludarabine + Clofarabine is a phase 2 stage product being developed by Race Oncology for Myelogenous Leukemia, Acute. The current trial status is unknown. This product is registered under clinical trial identifier NCT04989335. Target conditions include Myelogenous Leukemia, Acute.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04989335 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Myelogenous Leukemia, Acute
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bisantrene | Race Oncology | Phase 2 | 44 |
| Milademetan + AZA + Milademetan | Daiichi Sankyo | Phase 1 | 33 |
| micafungin + posaconazole | Astellas Pharma | Approved | 85 |
| decitabine Induction Chemotherapy + Induction Chemotherapy | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Gemtuzumab ozogamicin | Eisai | Phase 2 | 52 |
| Ondansetron + Palonosetron | Eisai | Phase 2 | 52 |
| decitabine (5-aza-2'deoxycytidine) | Eisai | Phase 2 | 52 |
| Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine | Eisai | Phase 2/3 | 65 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| KW-2449 | Kyowa Kirin | Phase 1 | 33 |
| flumatinib + imatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-199 | AbbVie | Phase 2 | 52 |
| Posaconazole + ABT-199 + Decitabine + Azacitidine | AbbVie | Phase 1 | 33 |
| Venetoclax + Cytarabine | AbbVie | Phase 1/2 | 41 |
| AZD4877 | AstraZeneca | Phase 1 | 33 |
| MK-8776 + Cytarabine | Merck | Phase 1 | 33 |
| MK0457 | Merck | Phase 1 | 33 |